# A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

> **NCT05169905** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 9 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **COMBINATION_PRODUCT:** RSV MAT vaccine
- **COMBINATION_PRODUCT:** dTpa vaccine

## Key facts

- **NCT ID:** NCT05169905
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169905, "A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05169905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*